TIDMHIK

RNS Number : 7997Q

Hikma Pharmaceuticals Plc

08 June 2018

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 8 June 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)

(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee has made the following nil cost option under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to a Person Discharging Managerial Responsibility ("PDMR") of the Company.

The Award under the EIP was made on 7 June 2018 at a price of 1,035 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2017, in accordance with the EIP rules) as follows:

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Surendera Tyagi

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Surendera Tyagi 
 2    Reason for the notification 
 a)   Position/status           Chief Scientific Officer and Global Head of 
                                 R&D 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             (Shares) 
       instrument, type          ID Code: GB00B0LCW083 
       of instrument 
       and identification 
       code 
 b)   Nature of the             The Company granted the named individual above 
       transaction               a nil-cost option award to acquire Shares under 
                                 Element C of the 2014 Executive Incentive Plan 
                                 (EIP). Shares under Element C EIP award will 
                                 vest after 3 years, subject to continued employment. 
 c)   Price(s) and              Price(s): GBP10.35 
       volume(s)                 Volume(s): 28,818 
 d)   Aggregated information    N/A 
 e)   Date of the transaction   7 June 2018 
 f)   Place of the              London Stock Exchange (XLON) 
       transaction

Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHBGGDLLSGBGII

(END) Dow Jones Newswires

June 08, 2018 06:50 ET (10:50 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Hikma Pharmaceuticals Charts.